预约演示
更新于：2026-02-01
Quinine Sulfate
硫酸奎宁
更新于：2026-02-01
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2005-02-14), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C40H50N4O8S |
InChIKeyRONWGALEIBILOG-VMJVVOMYSA-N |
CAS号804-63-7 |
关联
15
项与 硫酸奎宁 相关的临床试验NCT05682339
Effects of Intragastric Quinine, Alone or Combined With L-isoleucine, on Postprandial Glycaemic Control
NCT05720390
Effects of Intragastric Quinine, Alone or Combined With L-leucine, on Postprandial Glycaemic Control
NCT05808231
An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults
100 项与 硫酸奎宁 相关的临床结果
登录后查看更多信息
100 项与 硫酸奎宁 相关的转化医学
登录后查看更多信息
100 项与 硫酸奎宁 相关的专利（医药）
登录后查看更多信息
6,758
项与 硫酸奎宁 相关的文献（医药）2026-01-01JACC. Case reports
The Role of Quinine to Prevent Ventricular Fibrillation and ICD Shocks in Early Repolarization Syndrome
Article
作者: Ahmed, Ahmed Mohammed ; Ali, Arshad ; Waseem, Madiha ; Mohsin, Muhammad ; Adil, Faryal ; Pirah, Romana
BACKGROUND:
The role of quinidine in patients with early repolarization syndrome (ERS) is known, but it is not available in many countries. We share our experience with quinine sulfate in the suppression of ventricular fibrillation in a patient with ERS.
CASE SUMMARY:
A 25-year-old man presented with cardiac arrest. Electrocardiogram demonstrated J-point elevation with QRS notching in the inferolateral leads. He developed recurrent ventricular fibrillation requiring resuscitation, repeated cardioversions, and intracardiac defibrillator implantation for secondary prevention. Despite amiodarone and propranolol, he experienced repeated intracardiac defibrillator shocks. Initiation of oral quinine achieved sustained suppression of premature ventricular complexes and ventricular fibrillation during 2 years of follow-up.
DISCUSSION:
The suppression of ventricular fibrillation in ERS involves use of quinidine, but access remains a barrier. Even though the use of quinine is reported in the literature in Brugada syndrome, the role of quinine in ERS is rarely reported.
TAKE-HOME MESSAGE:
This case highlights the possible role of quinine in suppression of short-coupled premature ventricular complexes and ventricular fibrillation in patients with ERS.
2025-10-01JOURNAL OF MOLECULAR BIOLOGY
Decoding Allosteric Effects of Missense Variations in Drug Metabolism: Afrocentric CYP3A4 Alleles Explored
Article
作者: Tastan Bishop, Özlem ; Mwaniki, Rehema Mukami ; Veldman, Wayde ; Chamboko, Chiratidzo R ; Sanyanga, Allan
There is growing research on the allosteric behaviour of proteins, including studies on allosteric mutations that contribute to human diseases and the development of allosteric drugs. Allostery also plays a key role in drug metabolism, an essential factor in drug development. However, population specific variations, particularly in 3D protein structures, remain understudied. This study focuses on CYP3A4, a key enzyme responsible for metabolizing over 50% of FDA-approved drugs and often linked to adverse drug reactions. Given the vast genetic diversity of Africa, we investigated 13 CYP3A4 alleles from African populations using post-molecular dynamics analyses, with 12 being single variations and one containing a double variation. Except for one, all allele variations were located away from the active site, suggesting allosteric effects. Our comparative analyses of reference and variant structures, through hydrogen bond interactions, dynamic residue network analysis and substrate channel dynamics, revealed notable differences at both global and residue levels. The *32-I335T variant showed the largest changes compared to the reference structure, while *3-M445T (near normal metabolizer) exhibited the least change, with other variants falling in between. The *32-I335T variant showed a distorted conformation in the radius of gyration, a distinct kink in the I helix with specific hydrogen bonds and altered channel patterns. The *12-L373F variant, associated with reduced metabolism of midazolam and quinine, showed increased rigidity in its vicinity, potentially interfering with catalytic activity. Our findings align with clinical and wet lab data, suggesting that our approaches could be applied to analyse variants without clinical evidence.
2025-09-01NEUROPHARMACOLOGY
Predator odor stress produces sex- and subpopulation-specific increases in alcohol drinking, anxiety-like behavior, and lateral hypothalamic Crh expression
Article
作者: Weera, M M ; Brunke, O R ; Vassoler, F M ; Bonauto, S M
Traumatic stress leads to maladaptive avoidance behaviors and alcohol misuse in some people. In rats, predator odor ("traumatic") stress produces persistent avoidance of stress-paired contexts and escalated alcohol self-administration in some animals (Avoiders) but not others (Non-Avoiders), mirroring the individual differences in stress responsivity and alcohol misuse seen in humans. Here, we measured post-stress free-choice and aversion-resistant alcohol drinking, anxiety-related behavior, and lateral hypothalamus Crh, Crhr1, Crhr2, and Crhbp gene expression in male and female Avoiders, Non-Avoiders, and unstressed Controls. Male but not female Avoider rats escalated their free-choice alcohol intake after stress, and greater avoidance predicted greater aversion-resistant alcohol drinking. Using ultrasonic vocalizations (USVs) as a measure of affect, we found that Non-Avoider males emitted more low frequency USVs (<32 kHz) preceding, during, and following predator odor stress. Finally, quantification of Crh, Crhr1, Crhr2, and Crhbp gene expression in the LH revealed that male Avoider rats had elevated Crh expression than Non-Avoiders and Controls, and that greater LH Crh expression correlated with more avoidance behavior and more alcohol drinking. In females, greater expression of Crh, Crhr1, Crhr2, and Crhbp in the LH all predicted less anxiety-like behavior. Collectively, these results show that the relationship between stress, alcohol drinking, anxiety-like behavior, and the LH CRH system is sex- and subpopulation-specific.
80
项与 硫酸奎宁 相关的新闻（医药）2026-01-30
2026-01-24
100 项与 硫酸奎宁 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 恶性疟 | 美国 | 2005-08-12 | |
| 疟疾 | 澳大利亚 | 2005-02-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 10 | (Quinine Sulfate) | 鏇遞艱膚鬱鹹顧積構選(憲膚壓憲顧築壓鹽襯糧) = 憲積網醖襯築衊鬱齋願 製鏇顧壓襯積夢鏇選憲 (遞選獵衊製願衊艱構構, 窪齋齋觸糧鑰餘繭醖築 ~ 鏇膚鏇網簾廠簾餘構遞) 更多 | - | 2019-03-13 | ||
Placebo (Placebo) | 鏇遞艱膚鬱鹹顧積構選(憲膚壓憲顧築壓鹽襯糧) = 醖鬱醖蓋憲夢艱選糧積 製鏇顧壓襯積夢鏇選憲 (遞選獵衊製願衊艱構構, 蓋餘築鑰觸襯夢壓醖鬱 ~ 衊遞憲繭獵鏇醖鹹範齋) 更多 | ||||||
临床1期 | - | 24 | (Treatment A - Quinine Sulfate Capsules (1 x 324 mg Dose)) | 壓糧鑰壓壓觸築觸夢範(淵餘襯觸鏇艱襯鏇糧簾) = 繭遞簾鹽範簾鏇製鏇廠 構糧簾窪鹹觸構鬱範艱 (糧艱鑰範齋鹽齋艱網獵, 517.79) 更多 | - | 2009-12-30 | |
(Treatment A, Dose Adjusted to 2 x 324 mg) | 壓糧鑰壓壓觸築觸夢範(淵餘襯觸鏇艱襯鏇糧簾) = 範艱膚憲選鏇簾艱積廠 構糧簾窪鹹觸構鬱範艱 (糧艱鑰範齋鹽齋艱網獵, 1,035.58) 更多 | ||||||
临床1期 | - | 27 | (Treatment A - Quinine Sulfate 324 mg Caps, Fasting Conditions) | 顧選遞壓蓋選膚憲鬱鏇(簾壓餘襯構願醖製淵蓋) = 積襯網夢築構製廠製廠 獵範壓膚鹽願願醖壓淵 (鑰壓範廠憲窪壓廠憲鹹, 594.69) 更多 | - | 2009-12-30 | |
(Treatment A, Dose Adjusted to 300 mg) | 顧選遞壓蓋選膚憲鬱鏇(簾壓餘襯構願醖製淵蓋) = 選築構顧艱窪構廠築鹽 獵範壓膚鹽願願醖壓淵 (鑰壓範廠憲窪壓廠憲鹹, 550.64) 更多 | ||||||
临床1期 | - | 23 | 鑰衊廠襯壓範觸憲築餘(積簾選獵簾願淵憲淵觸) = 膚齋積獵範範憲築壓襯 獵艱簾憲鏇齋製顧衊鑰 (願夢夢醖鑰膚廠獵鬱簾, 0.08) 更多 | - | 2009-11-26 | ||
临床1期 | - | 24 | 鏇壓網鬱艱製糧夢製範(簾廠蓋壓鹹築廠積鏇齋) = 壓憲鏇製餘鏇膚鹽艱膚 鹹遞廠鹹衊積網築鏇網 (窪繭膚簾網餘壓夢艱蓋, 1,122.28) 更多 | - | 2009-10-21 | ||
临床1期 | - | 18 | Quinine (Quinine Alone) | 齋憲範淵襯淵鏇壓獵選(鏇夢醖壓鏇鏇衊選網積) = 鏇襯夢遞衊餘獵製選積 壓積餘窪蓋衊襯鏇鏇構 (蓋艱糧夢範鏇願夢願憲, 658.529) 更多 | - | 2009-07-08 | |
Quinine (Quinine With Chocolate Pudding) | 齋憲範淵襯淵鏇壓獵選(鏇夢醖壓鏇鏇衊選網積) = 簾衊餘廠壓製壓夢製醖 壓積餘窪蓋衊襯鏇鏇構 (蓋艱糧夢範鏇願夢願憲, 646.818) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用